MDNA

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PR, Combination therapy, VLS, MSI-H, PD, LFT, RDE, Duodenal cancer, Patient, Hypertelorism, Radiation, MCC, MDNA, AACR, TSX, DLT, Pancreatic cancer, Safety, Regulatory T cell, Melanoma, Cancer, BCC, NK, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024
TME, Toxicity, Metastasis, Enzyme, Survival, Cleavage, IL-2R, Brain, Patient, Tumor microenvironment, Mouse, Breast, Cancer, Prostate, Science, MDNA, AACR, TSX, Neoplasm, Metalloproteinase, Breast cancer, Poster, Medical imaging

TORONTO and HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data on MDNA113, the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, an IL-13R⍺2 (Interleukin-13 receptor alpha2) specific superkine featuring unique masking and tumor targeting characteristics, were presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9th, 2024.

Key Points: 
  • Key findings presented at the conference include:
    When not activated, MDNA113 shows reduced IL-2R agonism with no change to PD-1/PDL-1 blockade activity.
  • MDNA113 selectively binds IL-13R⍺2 positive tumor cells in vitro, and durably accumulates (>7 days) in IL-13R⍺2 positive tumors in mice.
  • Single neoadjuvant treatment with MDNA113 in a highly invasive orthotopic 4T1.2 breast cancer model significantly increases survival by preventing metastasis.
  • It will be also available on the Scientific Presentations page of Medicenna’s website following the conclusion of the 2024 Annual Meeting of AACR.

Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Thursday, April 4, 2024
Webcast, MDNA, Metro Toronto Convention Centre, OTCQB, TSX, Conference

TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

Key Points: 
  • TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
  • Details on the presentation are as follows:
    Webcast and replay information for this event will also be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/ .
  • The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector.
  • Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
OTCQB, TSX, AACR, MDNA, Safety, Abstract, Pharmaceutical industry

TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place in San Diego, CA from April 5-10, 2024.

Key Points: 
  • TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place in San Diego, CA from April 5-10, 2024.
  • The Company will present an update from its Phase 1/2 ABILITY-1 Study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, the only long-acting, ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist in clinical development.
  • In addition, pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 Superkine, will also be presented at the conference.
  • Details for the abstracts and poster presentations are as follows:
    Title: Results from Monotherapy Dose Escalation of MDNA11, a Long-acting IL-2 Superkine, in a Phase 1/2 Trial Show Evidence of Single-agent Activity in Advanced Solid Tumors
    Following the conclusion of the AACR 2024 Meeting, a copy of the posters will be available on the “ Events and Presentations ” page of Medicenna’s website.

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
IPR, Research, CMO, Decompression (diving), PR, Society, Bifunctional, MNP, PRS, Bank statement, Melanoma, OTCQB, ICI, Toronto Stock Exchange, SITC, CBV, Annual general meeting, European Medicines Agency, Partnership, BTD, Highlight, AACR, Conference, Safety, Clinical trial, Survival, Neurology, CFO, EMA, Enzyme, MD, ECA, FDA, TSX, Cancer, EDGAR, Pembrolizumab, Response, MDNA, SNO, Patient, Pharmaceutical industry

Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.

Key Points: 
  • Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.
  • Clinical update from the combination arm of the ABILITY-1 study evaluating MDNA11 in with KEYTRUDA® expected in H1 and H2 of 2024.
  • Research and development expenses of $3.0 million were incurred during the quarter ended December 31, 2023, compared with $2.9 million incurred in the quarter ended December 31, 2022.
  • General and administrative expenses of $1.8 million were incurred during the quarter ended December 31, 2023, compared with $2.0 million during the quarter ended December 31, 2022.

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, February 13, 2024
OTCQB, Merck, Doctor of Philosophy, TSX, Cancer, Pembrolizumab, MDNA, CPI, Merck & Co., Patient, JITC, Mouse, Pharmaceutical industry

The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors.

Key Points: 
  • The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors.
  • “Dosing the first patient in the combination arm with MDNA11 and KEYTRUDA® is a significant milestone for Medicenna and are excited with the progress of our novel IL-2 superkine," said Fahar Merchant, PhD, President and CEO of Medicenna.
  • “By combining MDNA11 with KEYTRUDA®, we are building upon the promising data generated to date by MDNA11 as a single agent.
  • MDNA11, with its uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Medicenna Announces Appointment of New Auditor

Retrieved on: 
Friday, January 12, 2024
MDNA, Former, CFO, CBV, CPA, OTC, TSX, MNP, MNP LLP, National instrument, PwC, Audit

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP (“MNP” or “Successor Auditor”) as auditor.

Key Points: 
  • TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP (“MNP” or “Successor Auditor”) as auditor.
  • The board of directors of the Company accepted the resignation of PricewaterhouseCooper LLP (the “Former Auditor”) and appointed MNP as the new auditor until the next annual general meeting of shareholders of the Company.
  • The Company’s board of directors and audit committee each approved the resignation of the Former Auditor and the appointment of MNP.
  • Mr. Hodgins was the founding CFO of Medicenna and is the current contract CFO of several public Canadian companies.

Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

Retrieved on: 
Tuesday, January 9, 2024
MSD, MDNA, Patient, Neoplasm, PD-1, Mouse, OTCQB, Cancer, TSX, Pembrolizumab, CPI, JITC, Pharmaceutical industry

“We are very pleased to announce initiation of the combination study of MDNA11 and the PD-1 inhibitor, pembrolizumab, the leading checkpoint inhibitor therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.

Key Points: 
  • “We are very pleased to announce initiation of the combination study of MDNA11 and the PD-1 inhibitor, pembrolizumab, the leading checkpoint inhibitor therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.
  • “Having established an appropriate dose for monotherapy as well as demonstrating its early clinical validation we believe MDNA11 may further enhance anti-tumor activity when combined with pembrolizumab in patients that do not respond or develop resistance to checkpoint therapy.
  • We look forward to reporting preliminary results from both the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024.”
    In the Phase 1 monotherapy dose escalation and dose evaluation portions of the study, MDNA11 was well tolerated with promising single-agent activity.
  • MDNA11, with its uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Retrieved on: 
Monday, January 8, 2024
Medical Devices, Women, Seniors, Men, Health Technology, Biotechnology, General Health, Consumer, Health, Oncology, Liver, Database, MDNA, Medicine, Multimedia, Stomach, Woman, Ovarian cancer, Acquisition, Lung, Breast, WHO, Colorectal cancer, Prevalence, Mitochondrion, Prostate cancer, World Health Organization, Cancer, Liquid biopsy, Knowledge, Endometriosis, American Cancer Society, Prostate-specific antigen, Biomarker, Diagnosis, Global health, Overdiagnosis, Security (finance), PSA, Medical imaging

This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics.

Key Points: 
  • This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics.
  • The platform includes a rich biomarker portfolio addressing a wide range of high-priority health concerns beyond oncology, extending into areas of substantial medical need.
  • Highlights from the asset portfolio include:
    The Mitomic Endometriosis Test (MET™) is in development as a blood-based assay for diagnosis of endometriosis.
  • The overarching goal is to enhance clinical outcomes by offering non-invasive or minimally invasive testing at the early stages of disease progression.

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

Retrieved on: 
Tuesday, December 19, 2023
TSX, Toronto Stock Exchange, MDNA, OTCQB, Certification

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023.

Key Points: 
  • TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023.
  • Medicenna’s shares will continue to trade on the Toronto Stock Exchange under its symbol MDNA.
  • The OTCQB stands as the primary platform for U.S. and international companies in the entrepreneurial and development stages, dedicated to delivering a high-quality trading and information experience for their U.S. investors.
  • Streamlined market standards enable Canadian companies to provide a strong baseline of transparency to inform and engage U.S. investors.